[Methotrexate, liver and rheumatoid arthritis in tropical areas].
D000686:Amyloidosis / Q000139:chemically induced* / Q000145:classification / Q000453:epidemiology / Q000628:therapy; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology; D001706:Biopsy; D002353:Carrier State; D056486:Chemical and Drug Induced Liver Injury / Q000145:classification / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D016903:Drug Monitoring; D019353:Endemic Diseases / Q000517:prevention & control / Q000706:statistics & numerical data; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology; D006801:Humans; D006975:Hypertension, Portal / Q000139:chemically induced* / Q000145:classification / Q000453:epidemiology / Q000628:therapy; D008107:Liver Diseases / Q000145:classification / Q000453:epidemiology / Q000628:therapy; D008727:Methotrexate / Q000009:adverse effects*; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D014330:Tropical Medicine; D014762:Viral Interference / Q000187:drug effects
Méthotrexate, foie et polyarthrite rhumatoïde en milieu tropical.